alr2-in-1

ALR2-IN-1 is a potent and selective ALR2 inhibitor with an IC50 value of 1.42 μM. ALR2-IN-1 possesses both antiglycemic and antioxidant activities and can be used to study the complications of diabetes.

ALR2-IN-10 (Compound 23) is a weak inhibitor of aldose reductase 2 (Aldose Reductase2), showing an inhibition rate of 6% at a concentration of 27 μM. It is applicable in research related to diabetic complications.

ALR2-IN-9 is a potent inhibitor of ALR2 with an IC50 of 21.8 nM, demonstrating excellent antioxidant activity with an EC50 of 2.8 μM in DPPH free radical scavenging. It directly interacts with reactive oxygen (ROS) and reactive nitrogen species (RNS), blocking free radical chain reactions, and acts as an endogenous enzyme antioxidant regulator to modulate catalase (CAT) and superoxide dismutase (SOD) enzyme functions. By influencing the PI3K/Akt/Nrf2 pathway, ALR2-IN-9 inhibits excessive mitochondrial superoxide production induced by hyperglycemia in vitro and ameliorates oxidative stress induced by CuSO4 and H2O2 in vivo models. The compound also extends the lifespan of *Caenorhabditis elegans* by regulating stress response genes such as PMK-1 and shows potential as an anti-aging candidate. ALR2-IN-9 can be utilized in diabetes complication research.

Aldose reductase-IN-4 (compound IIc) is an inhibitor of aldose reductase with IC50 values of 11.70 μM for ALR1 and 0.98 μM for ALR2, respectively [1].

ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) inhibitor (IC50: 3.26 μM) and aldose reductase (ALR2) inhibitor (IC50: 3.06 μM) with anticancer effects.